This is a randomized, controlled multi-site, multi-national clinical trial conducted in
Thailand and Malaysia for naïve Asian adults (males or females), 18 years of age and older
presenting with advanced HCC (BCLC stage C) including subjects with vascular involvement
and/or extrahepatic spread (not eligible for TACE, surgery or locoregional treatment) with
Child-Pugh stage A or B liver function and either unable to assess, or not eligible for,
sorafenib first line treatment. 180 subjects will be randomized 2:1 to AlloStim®
immunotherapy vs Physician's Choice of Best Supportive Care or FOLFOX4 chemotherapy.